Clinical trial
An Open-label Extension Study of Treprostinil Administered Via a Soft Mist Inhaler (SMI) in Participants With Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease (PH-COPD)
NCT07923526 is registered in ClinicalTrials.gov with United Therapeutics as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing
Registry record
As filed in ClinicalTrials.gov.
- Title
- An Open-label Extension Study of Treprostinil Administered Via a Soft Mist Inhaler (SMI) in Participants With Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease (PH-COPD)
- Lead sponsor
- United Therapeutics
- Phase
- Phase 2/3
- Overall status
- Not yet recruiting
- Start date
- March 31, 2027
- Completion date
- September 30, 2034
- Enrollment
- 400 (estimated)
- Sites
- 15
Conditions
As the registry lists them; a condition with its own page is linked.
pulmonary hypertension associated with chronic obstructive pulmonary disease
Arms
As registered; 1 arm.
-
treprostinil SMI
Inhaled treprostinil administered via a SMI at concentrations of 1.34, 2.68, 4.02, 5.36 and 6.70 mg/mL
Primary endpoints
Registered primary outcome measures; 9 primary.
-
Incidence of adverse events (AEs) and serious AEs (SAEs)
Number and type of AEs and SAEs observed in participants during and after use of treprostinil SMI.
-
Change in Forced Expiratory Volume in One Second (FEV1) as % predicted
FEV1 is a standard indicator of lung function and measures the maximal amount of air forcefully exhaled in 1 second.
-
Change in Forced Vital Capacity (FVC) in mL
FVC is a standard indicator of lung function and measures the amount of air a person can forcefully and quickly exhale after taking a deep breath.
-
Change in FEV1/FVC ratio
The FEV1/FVC ratio measures how much air is exhaled in one second compared to a full breath. This helps determine if the lung condition is restrictive or obstructive and its severity.
-
Change in Total Lung Capacity (TLC) in mL
TLC is a standard indicator of lung function and measures the maximum volume of lung capacity after very deep inhalation.
+4 more primary endpoints
Lead sponsor's other trials
United Therapeutics, most recent start first.
+79 more trials See the organization page
Similar trials
Same condition (Hypertension, Pulmonary) and phase, most recent start first.
+17 more trials See the condition page